No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS
about
Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorderA new look at an old drug: neuroprotective effects and therapeutic potentials of lithium saltsTherapeutic neuroprotective agents for amyotrophic lateral sclerosisImproving the predictive value of interventional animal models dataEGFR inhibitor erlotinib delays disease progression but does not extend survival in the SOD1 mouse model of ALSLithium-mediated protection against ethanol neurotoxicityMetformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female miceNFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapyA randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosisLithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.Dexpramipexole is ineffective in two models of ALS related neurodegeneration.Regulation of autophagy by mTOR-dependent and mTOR-independent pathways: autophagy dysfunction in neurodegenerative diseases and therapeutic application of autophagy enhancers.GSK-3 in Neurodegenerative Diseases.Autoimmunity in amyotrophic lateral sclerosis: past and present.Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disordersNeuroprotective action of lithium in disorders of the central nervous system.Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis.Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.Endolysosomal Deficits Augment Mitochondria Pathology in Spinal Motor Neurons of Asymptomatic fALS Mice.Interleukin-6 Deficiency Does Not Affect Motor Neuron Disease Caused by Superoxide Dismutase 1 Mutation.Triheptanoin Protects Motor Neurons and Delays the Onset of Motor Symptoms in a Mouse Model of Amyotrophic Lateral SclerosisDysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS.C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice.Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's ResearchLithium in neuropsychiatry: a 2010 update.Autophagy and Its Comprehensive Impact on ALS.Protein recycling pathways in neurodegenerative diseases.New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models.Neurobiology of axonal transport defects in motor neuron diseases: Opportunities for translational research?Autophagy Dysregulation in ALS: When Protein Aggregates Get Out of Hand.ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosisWhy lithium studies for ALS treatment should not be halted prematurely.Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons.Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease.Effect of Imipramine, Paroxetine, and Lithium Carbonate on Neurobehavioral Changes of Streptozotocin in Rats: Impact on Glycogen Synthase Kinase-3 and Blood Glucose Level.Characterisation of the pathogenic effects of the in vivo expression of an ALS-linked mutation in D-amino acid oxidase: Phenotype and loss of spinal cord motor neurons.Lithium treatment in amyotrophic lateral sclerosis: do we have enough trials?Distinct roles for motor neuron autophagy early and late in the SOD1G93A mouse model of ALS.Focus on the Role of D-serine and D-amino Acid Oxidase in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS).
P2860
Q24626017-19B53449-3F1D-49F2-A5A4-7594EF7D98D8Q26741164-85C123AC-43B5-4F4F-8967-F30380FC7210Q27015029-FF775511-48FF-44A8-9DBC-7F4F28CE121EQ27026822-C7692455-51CB-4A54-9B63-F5B1CAC992C6Q27322781-CC4472BE-D724-4FEA-AED3-D17FB12A6776Q28397186-52BA5EE8-4395-4E87-A483-349AEF6159A7Q28476761-9F14BDD1-0DBC-479D-95AF-175DF2F4A2B8Q28586033-372C06DF-B723-4B31-BD42-1BBDF9AE6B7BQ28728672-D4DD77C9-EAB0-4CCE-A966-A8BCD76D39ABQ34648924-2698CBE8-8624-4287-A612-328F7B4076A8Q34744144-A9018E97-B7D3-49C8-B18C-4319B082A45BQ34995420-BB18B4CB-7E94-4287-BF08-1CE9C77B0FBCQ35001040-D0883439-D1EB-4010-8981-A0B8EC5CFE1DQ35147143-03BC1EE1-4E43-4320-8CF5-04B365D6C1A5Q35197096-1431E5F6-843C-4F75-AAAA-2C13891FFC53Q35212429-7683361A-AC75-4B8C-B03A-8F6706777D8EQ35501802-CB1D8F3A-2641-4434-B1EC-2D7DFD654BABQ35750311-E7AAB735-D97E-4E3E-B65B-FC106DF99DF4Q35879849-3C4C7E26-C060-4974-9698-EE2B351287A9Q35986943-A90FF046-9A7C-407D-B163-A5D78E5733E3Q36114275-D3233EFD-35E2-4832-AB19-FBA35B39CBEFQ36270953-FA478D09-B464-49D4-84AE-35BB0450F1F4Q36691051-29F9DD8B-6F82-4BBE-8EDA-2AE6FE8306B2Q36925891-39768EDC-6C5D-49E1-9694-A343573A65ADQ37287403-A774190D-ABA6-48D4-9687-B24E83B09DDBQ37848442-182A5517-C341-4C52-BEEB-917E59F75FF8Q38029001-C60BCA49-4797-4B00-BA17-2D22E798E9F4Q38230383-4AE264B1-EAC4-4500-AD0E-43B5F927F4E8Q38701109-60C5B5C4-49AE-48E5-958A-E0EF3041449CQ39149919-06F4881D-74C8-4108-A6D4-A3C528D02A51Q41525479-BBBCA81B-4D7F-4035-B971-E15A6199FA82Q41865521-F8B6132C-D1D4-4769-B9FE-D4228D509D9EQ41976842-06B393D9-04EA-4DD8-9F54-4BE47C58B787Q44193974-BAC5C00B-5049-45C1-888A-4EF0E6EC34E3Q44597957-5136195B-54C5-45B1-9E0A-BFB84B55EC78Q46866200-32EF540B-E216-4F3D-B619-060B9DDC0E09Q47118571-D32AC56E-B608-443A-939F-0700E7092468Q47574212-9FE1B0CD-0156-4B7A-8322-9D96E5FFA335Q48114502-2893344E-C44A-4D9B-87B4-3BFDEDF495B4Q50331220-AFD0D7A7-0627-4AD4-BAB8-C4EA00B1BA9C
P2860
No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS
description
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2009)
@fr
articolo scientifico (pubblicato il 2009)
@it
artigo científico (publicado na 2009)
@pt
artículu científicu espublizáu en 2009
@ast
im Januar 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: 2009)
@en
vedecký článok (publikovaný 2009)
@sk
videnskabelig artikel (udgivet 2009)
@da
name
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@ast
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@en
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@nl
type
label
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@ast
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@en
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@nl
prefLabel
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@ast
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@en
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@nl
P2093
P2860
P3181
P1433
P1476
No benefit from chronic lithiu ...... rd mouse model of familial ALS
@en
P2093
Joshua Kidd
Kenneth Thompson
Steven Perrin
P2860
P3181
P356
10.1371/JOURNAL.PONE.0006489
P407
P577
2009-01-01T00:00:00Z